FDA halts California drugmaker’s CAR-T trial after patient death

Poseida is waiting on a formal action from the FDA and preparing recommendations to permit the trial to resume, the drugmaker stated..

The client had metastatic castrate-resistant prostate cancer and passed away of liver failure 19 days after getting the CAR-T treatment. He had missed 2 follow-up gos to and developed signs that caused him being hospitalized, according to the SEC filing..

The drugmakers shares fell 35 percent after the statement.

The stage 1 trial was investigating a CAR-T gene therapy called P-PSMA-101, created to treat prostate cancer..

The FDA halted San Diego-based drugmaker Poseida Therapeutics clinical trial of a CAR-T therapy after a patient passed away, according to an Aug. 17 Securities and Exchange Commission filing.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by click on this link.

Maia Anderson –
Tuesday, August 18th, 2020
Print|Email.

More articles on drug store: CVS partnering with Delta Air Lines for quick COVID-19 screening programSanofi inks $3.68 B offer to buy California autoimmune drugmakerUS to check advantages of remdesivir with 2nd drug.